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 1. Introduction 
 Microneedle arrays (MN) are minimally-invasive devices that 
painlessly by-pass the skin’s  stratum corneum, which is the prin-
cipal barrier to topically-applied drugs. [ 1 ] MN (50–900  μ m in 
height, up to 2000 MN cm  − 2 ) have been extensively investigated 
in recent years as a means to enhance transdermal drug and vac-
cine delivery. [ 2–10 ] No MN array-based drug delivery systems are 
presently marketed, due to the relatively recent developments 
that have made such devices a reality. Indeed, the subsequently 
rapid progression of the fi eld has inevitably led to some diffi -
culties: silicon, the most commonly-employed MN material to 
date, has dubious biocompatibility and broken silicon or metal 
MN could cause skin problems; [ 5 ] solid, non-coated MN require 
a two-step application process, which is undesirable for patient 
use [ 5 , 6 ] ( Figure  1 a); accurately coating MN 
is diffi cult and these coated MN subse-
quently only deliver a very small amount 
of drug as a bolus [ 2–4 , 6 ] (Figure  1 b); MN-
induced holes normally close over very 
quickly ( < 1 h). The rate of hole closure can 
be slowed by heavy occlusion, but cannot 
be prevented; [ 7 ] biomolecules can be sig-
nifi cantly degraded by the heating used to 
produce polymeric MN from molten poly-
mers or carbohydrates [ 2–4 , 8 ] (Figure  1 c); 
and hollow MN have only one outlet 
and can become blocked by compressed 
dermal tissue. [ 2–4 ] (Figure  1 d). 
 Recently, MN loaded with drug have 
been prepared under ambient processing 
conditions from aqueous gels based on 
FDA-approved polymers. [ 9 ] Such systems, 
which dissolve in skin interstitial fl uid to 
release their drug payload, have overcome 
many of the above diffi culties. However, 
while transdermal delivery of small ( < 500 daltons) water-soluble 
molecules from both MN and baseplate is possible with such 
systems, only macromolecules (e.g., insulin) located in the MN 
themselves are deliverable. [ 10 ] In addition, while the polymers 
employed for fabricating these MN have long-established safety 
profi les, they have never before been administered intrader-
mally. Regulatory authorities will inevitably require extensive 
studies investigating routes of metabolism and elimination, 
possibly delaying commercialisation. Since MN materials will 
encounter viable skin cells, unlike conventional transdermal 
and topical drug delivery systems, regulators may also require 
MN systems to be sterile. Here we describe unique MN arrays 
prepared from crosslinked polymers which contain no drug 
themselves, as shown in Figures  1 e–h. Instead, they rapidly 
take up skin interstitial fl uid upon skin insertion to form con-
tinuous, unblockable, hydrogel conduits from patch-type drug 
reservoirs to the dermal microcirculation (Figure  1 f,g). Impor-
tantly, such MN, which can be fabricated in a wide range of 
patch sizes and MN geometries, can be easily sterilised, resist 
hole closure while in place and are removed completely intact 
from the skin (Figure  1 h). Delivery of macromolecules is no 
longer limited to what can be loaded into the MN themselves 
and transdermal drug delivery is now controlled by the crosslink 
density of the hydrogel system rather than the  stratum corneum, 
while electrically modulated delivery is also a unique feature. 
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hydrogel MN (with 600  μ m height, 300  μ m width at base, 
150  μ m interspacing, and 3  × 3 arrays) were determined as 
reported previously. [ 8 , 10 , 15 , 16 ] 
 2.3. In Vitro Permeation Studies 
 The ability of the novel hydrogel-forming MN in enhancing and 
controlling transdermal drug delivery was investigated by using 
six hydrophilic solute molecules of increasing molecular weight: 
fl uorescein-isothiocyanate labelled bovine serum albumin (FITC-
BSA), insulin, methylene blue (MB), caffeine (CF), theophyl-
line (TP), and metronidazole (MZT) with molecular weights of 
 ≈ 67,000,  ≈ 6000, 319.85, 194.19, 180.17, 171.15 Daltons, respec-
tively. For studies involving high-molecular weight molecules, 
a pore-forming agent (NaHCO 3 ) was added to the hydrogel 
formulation. Adhesive patches, as stated below, containing the 
above molecules at defi ned loadings, were then attached to the 
upper baseplates of hydrogel-forming MN, with the novel com-
posite system termed as “integrated MN” ( Figure  2 a). Permea-
tion was then investigated from this integrated MN system and 
compared with that of the adhesive patches alone. 
 Adhesive patches were prepared, by using a casting method, 
from aqueous blends of 10% w/w PMVE/MA and 5% w/w 
tripropyleneglycol methyl ether (TPM). [ 28 ] Required amounts 
of solute molecules were either added directly into the aqueous 
blends or dissolved in 0.01 M HCl prior to addition to the 
aqueous blends. An aliquot (2.7 g) of aqueous blend was cast 
 2. Materials and Methods 
 This study comprehensively investigated the utility of our novel 
hydrogel-forming MN arrays in transdermal drug delivery. 
Mechanical properties, in vitro/in vivo permeation of model 
drug substances, combined effect with iontophoresis (ITP), bio-
compatibility, and safety in human subjects were investigated. 
The methods for each study are detailed below. 
 2.1. Chemicals 
 Poly(methylvinylether/maelic anhydride) (Gantrez AN-139) was 
provided by ISP, Guildford, UK. Poly(ethyleneglycol) 10,000 
daltons and all drug substances were obtained from Sigma-
Aldrich, Poole, Dorset, UK. All other chemicals were of ana-
lytical reagent grade. 
 2.2. Preparation and Mechanical Testing of MN 
 Aqueous blends containing 15% w/w poly(methylvinylether/
maelic acid) (PMVE/MA) and 7.5% w/w poly(ethyleneglycol) 
10,000 (PEG) were utilized to fabricate MN by using laser-engi-
neered silicone micromould templates. [ 10 , 15 , 16 ] Optimum poly-
meric composition was determined in our previous hydrogel 
work. [ 11–13 ] MN were crosslinked (esterifi cation reaction) by 
heating at 80  ° C for 24 h. [ 11–13 ] Mechanical properties of these 
 Figure  1 .  Schematic representation of methods of MN application to the skin to achieve enhanced transdermal drug delivery. a–d) Traditional methods 
of MN-mediated drug delivery across skin. (a) uses solid MN that are applied and removed to create transient micropores, followed by application 
of a traditional transdermal patch. (b) uses solid MN coated with drug for instant delivery. MN areremoved after coating material dissolves. (c) uses 
soluble polymeric/carbohydrate MN containing drug that dissolve in skin interstitial fl uid over time, thereby delivering the drug. (d) uses hollow MN 
for delivery of fl uids containing drug. e–h) Our novel hydrogel-forming polymeric MN for controlled transdermal drug delivery. (e) shows an exploded 
view of our novel integrated hydrogel MN patch, which consists of a backing layer, a drug-loaded adhesive patch and a solid crosslinked hydrogel MN 
array. (f) shows application of the integrated hydrogel MN patch to the skin surface. This is followed by diffusion of water into the crosslinked integrated 
MN patch. (g) shows diffusion of water, which causes controlled swelling of the MN arrays, forming an in situ hydrogel conduit. This further results 
in liberation and diffusion of drug molecules from the adhesive patch through the hydrogel MN into the skin. (h) shows that the hydrogel MN arrays 
remain intact, even after removal from the skin, thereby leaving no polymeric material in the skin following drug delivery. 
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previously. [ 10 , 15 , 30 ] FITC-BSA was quantifi ed using a gradient 
HPLC method (Agilent Technologies 1200 Series, Stock-
port, UK) in which the separation was performed on a C 4 
(4.6 mm × 50 mm, 5  μ m) analytical column (Symmetry 300, 
Waters Ireland, Dublin). The mobile phase gradient consisted of 
0.1% triforoacetic acid (TFA) in acetonitrile (ACN) and 0.1% TFA 
aqueous solution. The gradient linearity changed from 20:80 
(ACN: TFA) to 90:10 in 8 min and continued for 1.0 min at the 
ratio of 90:10. The reversal to the initial conditions was attained 
within 1.0 min, followed by a 3.0 min re-equilibration period. 
The total analysis run time was 13.0 min. The injection volume 
was 20  μ l and elution fl ow rate was 1.0 ml min  − 1 . FITC-BSA 
was detected using a fl uorescence detector with excitation and 
emission wavelengths set at 490 nm and 520 nm, respectively. 
Data were processed using Agilent Rapid Res software. CAF 
was analyzed following modifi cation of a literature method. [ 31 ] 
Briefl y, an isocratic HPLC method was used with a reverse 
phase C-18 (Waters Spherisorb 5  μ m ODS 4.6  × 150 mm, 
Waters Ireland, Dublin) analytical column. The column was 
thermostated at 35  ° C. The mobile phase consisted of 90% of 
0.52% glacial acetic acid and 10% of 50% ACN: 50% tetrahydro-
furan. The fl ow rate was 1.0 ml min  − 1 . Sample injection volume 
was 50  μ l. UV detection was performed at 273 nm. Data were 
processed using Agilent Rapid Res software. MB was analysed 
into silicone moulds (30  × 30 mm 2 ) and dried under a gentle 
air fl ow for 48 h. Attaching the formed adhesive patches with 
gentle pressure to hydrogel-forming MN yielded the integrated 
MN system. 
 Transdermal permeation was investigated in vitro across 
dermatomed neonatal porcine skin (300–400  μ m thickness, 
previously shown by us to be the optimum skin model for 
prediction of in vivo performance of dissolving polymeric 
MN) [ 29 ] by using a modifi ed Franz-cell setup, as described pre-
viously. [ 10 , 15 , 16 ] Integrated MN were applied to the dermatomed 
skin by using a custom spring-activated applicator [ 16 ] at a 
force of 11.0 N per array. Adhesive patches were applied using 
gentle pressure. Sample volumes of 300  μ L were withdrawn, 
in triplicates, and analysed by the methods below. The release 
medium for FTIC-BSA was 0.05% w/w SDS in phosphate 
buffered saline (PBS) at pH 7.4, for insulin 0.1 M Tris buffer 
at pH 10 (due to stability issues) and for the other drug 
molecules PBS at pH 7.4 was used. 
 2.4. Analysis of Drug Permeation 
 Receptor medium samples for insulin, TP and MZT were 
analysed using validated analytical methods reported 
 Figure  2 .  Fabrication and mechanical properties of novel hydrogel MN arrays. a) The method of fabrication of the integrated hydrogel-forming MN 
system from aqueous polymeric blends using custom laser-engineered silicone micromoulds. b) Percentage reduction in height of hydrogel-forming 
MN following axial load, Means  ± S.D, n  = 45. c–e) Digital microscopic images of hydrogel-forming MN following axial compression; where c) MN 
were subjected to a force of 0.05 N per needle, d) MN were subjected to a force of 0.36 N per needle, and e) MN were subjected to a force of 1.42 N 
per needle. f,g) Digital microscope images of hydrogel-forming MN subjected to transverse forces; f) before application and g) after application of 
0.51 N per needle. h) A histogram depicting the percentage number of holes created in the  stratum corneum of neonatal porcine skin in vitro following 
application of a range of insertion forces. i) A digital image of methylene blue staining showing 100% MN penetration of the  stratum corneum of neo-
natal porcine skin in vitro, following application of an insertion force of 0.03 N per needle or greater. j) Forces required to break the MN base-plates 
and the angle of bending of the MN base-plates at break, Means  ± SD, n  = 6. The scale bar in (i) represents 200  μ m.  ∗ P  < 0.05 and  ∗ ∗  P  < 0.001. Error 
bars in b, h, and j indicate standard deviations. 
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at 664 nm using a UV microplate reader (Powerwave XS, Bio-
Tek Instruments Inc., Minooski, USA). 
 2.5. In Vitro ITP Studies 
 We further investigated the combined effect of integrated MN 
and ITP on in vitro permeation of TP, MB, fl uorescein sodium 
(FS), insulin and FITC-BSA. In this case, TP, MB and FS were 
loaded at a concentration of 3 mg cm  − 2 in the adhesive patches. 
FITC-BSA and insulin were loaded at concentration of 2.5 and 
5 mg cm  − 2 , respectively. The methodology for this study is sim-
ilar to that stated above. For studies involving application of an 
electrical current, an Ag electrode was used as the anode and 
an Ag-AgCl electrode used as the cathode. The delivery elec-
trode was placed directly on top of the integrated MN, whilst 
the return electrode was placed into the receiver medium via 
the side arm of the Franz cell. A commercially available power 
supply (Phoresor II, Iomed, Lake City, FL, USA) was used 
to deliver a current of 0.5 mA for a period of 6 h for in vitro 
studies. A sample volume of 300  μ l was collected at predeter-
mined time intervals and was assayed by the analytical methods 
described above. For samples containing FS, UV-spectroscopy 
was used at a  λ max of 497 nm. 
 2.6. In Vivo Studies 
 Delivery of insulin, FITC-BSA and MZT from the integrated 
MN (with 600  μ m height, 300  μ m width at base, 50  μ m inter-
spacing, & 19  × 19 arrays) was investigated in a rat model. For 
studies involving insulin, diabetic Sprague-Dawley rats were 
selected. The methodology was similar to that in our previous 
publication, which involved soluble MN. [ 10 ] Positive controls 
were performed by subcutaneously injecting bovine insulin 
solution in PBS pH 7.4 at a dose of 0.2 IU per animal. Inte-
grated MN based on adhesive patches containing 5 mg cm  − 2 
insulin were applied to the shaved skin (Gillette Mach 3 Power, 
Procter & Gamble, Hampshire, UK) on the rats’ backs by using 
the spring-activated applicator at a force of 11.0 N per array. 
Skin integrity was confi rmed using transepidermal water loss 
measurements made using a Defl in Vapometer (Defl in Tech-
nologies Kuopio, Finland) Following application, the integrated 
MN were held in place for 12 h with the help of a self-adhesive 
silicone sheet. 
 Blood samples were collected at pre-defi ned time intervals 
over a 12 h period by lateral tail vein prick and blood glucose 
levels (BGL) were measured using a glucometer (Accu-Check 
Aviva, Roche Ltd., Mannheim, Germany). Blood glucose levels 
were expressed as the percentage of initial BGL and calculated 
values were plotted against time to obtain blood glucose level-
time profi les. C max , denoting maximum% decrease in BGL, 
was calculated by subtracting the lowest% BGL from 100, as 
described elsewhere. [ 32 ] T max , denoting time required to achieve 
C max , was also reported. 
 Integrated MN containing FITC-BSA at 2.5 mg cm  − 2 loading 
in patches, were applied to healthy rats in an analogous way 
to insulin-loaded patches. A 0.25 ml aliquot of blood was 
drawn from the tail vein and collected into heparinised tubes 
(Microvette CB300, Sarstedt, Leicester, UK) at pre-defi ned time 
intervals over a period of 24 h. Plasma samples were obtained 
by centrifuging the collected blood samples at 10 000 rpm for 
10 min. All samples were analysed, within 2.0 h of collection 
using spectrofl uorimetry at an excitation wavelength of 490 nm 
and emission wavelength of 520 nm. 
 In vivo delivery of MZT from the integrated MNs was also 
investigated in rat models. The concentration of MZT versus 
time data obtained using the dried blood spot (DBS) method 
reported previously [ 30 ] was subjected to non-compartmental 
analysis (WinNonlin version 2.1, Pharsight, USA) to determine 
pharmacokinetic parameters, namely, area under curve (AUC), 
C max and T max . The steady state blood concentration (C ss ) of 
MZT after application of integrated MNs was calculated by 
using the equation:
 Css = AUC0−t/time  
 For in vivo studies, involving application of an electrical cur-
rent, a circular PVC ring (diameter 2.0 cm) was secured onto 
the rats back at the site of integrated hydrogel MN or adhesive 
patch application, using cyanoacrylate glue (Loctite Ltd, Dublin 
Ireland). The Ag electrode anode was then placed on top of the 
integrated MN or adhesive patch and held in place using a layer 
of double-sided adhesive tape (Henkel Ltd, Cheshire, UK) and 
an additional layer of Micropore tape (3M Ireland, Dublin). 
A second PVC ring (diameter 2.0 cm) was then secured at an 
adjacent site,  ≈ 2 cm away from the site of MN application. An 
aliquot of PBS pH 7.4 (1.0 ml) was then placed into the centre 
of this second PVC ring and an Ag-AgCl electrode was attached 
at the site using Micropore tape. The Phoresor™ II was used 
to deliver a current of 0.5 mA for a 2 h period after which the 
integrated MN and/or adhesive insulin/FITC-BSA patch were 
removed. 
 All animal experiments throughout this study were con-
ducted according to the policy of the Federation of European 
Laboratory Animal Science Associations (FELASA) and The 
European Convention for the protection of vertebrate Animals 
used for Experimental and Other Scientifi c Purposes, with 
implementation of the principle of the 3Rs (replacement, reduc-
tion, refi nement). 
 2.7. Biocompatability Evaluation 
 Biocompatability of PEG-crosslinked PMVE/MA-based 
hydrogel MN materials was performed in three different cell-
lines using an indirect test with two suspended cell-lines; 
fi broblasts (Balb/3T3) and keratinocytes (NRERT-1) [ 24 ] and a 3D 
keratinocyte organotypic raft culture. In all three cases, an MTT 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] 
assay was used to determine any cytotoxic effects. 
 To depict conditions pertaining to actual in vivo applica-
tion of MN, a Franz-cell setup was used to expose only the 
MN and not the baseplate to the extraction medium. A Silescol 
membrane was sandwiched between the receptor and donor 
compartment of the Franz-cells and the hydrogel-forming MN 
were applied in a similar manner as stated above. The receptor 
compartment was fi lled with 12.0 ml of DMEM (Dulbecco’s 
modifi ed Eagle’s medium) containing 4.5 g L  − 1 glucose, 2.0 mM 
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 Hydrogel-forming MN arrays were attached to waterproof 
plasters (Elastoplast, Beiresdorf, Hamburg, Germany) using 
double-sided adhesive tape. The spring loaded applicator was 
used to apply the MN-containing plasters Each volunteer was 
subjected to four interventions, a control plaster (without MN), 
a plaster containing MN baseplate only, a plaster containing 
hydrogel-forming MN (11  × 11 array) and a plaster containing 
hydrogel MN (19  × 19 array), as shown in Figure  6 c. 
 The study was conducted at a controlled room temperature 
of 20  ° C and a relative humidity of 45  ± 5%. The subjects were 
acclimatized in this room for 15 min prior to the start of the 
measurements. This study involved the application of water-
proof plasters, as described above, to the ventral forearm on 
three different occasions; 1) Patches applied and removed 
immediately (i.e., 0 h treatment group); 2) Patches applied and 
removed after 2 h (i.e., 2 h treatment group), and 3) Patches 
applied and removed after 24 h (i.e., 24 h treatment group). 
 Before application of the patches the ventral forearm were 
cleansed with a sterile swab (Boots Pharmaceuticals, Not-
tingham, UK) in each case. Four square areas ( ≈ 1.5 cm 2 ) were 
marked on the ventral forearm of each subject using a ballpoint 
pen. The square areas were located at equidistance on each 
forearm (Figure  6 c). Before the application of the plasters, TEWL 
and clinical photographs of skin were recorded, as described 
below. Following application of the plasters, the applicator was 
activated against each plaster to ensure consistent MN penetra-
tion in each volunteer (confi rmed using OCT, as described pre-
viously). [ 16 ] Immediately upon application, and after removal of 
the plasters (i.e., in 0, 2 and 24 h treatment groups), the VAS, 
TEWL and any change in skin colour was recorded in all the 
four interventions, as follows; 
 2.10. Visual Analogue Scale (VAS) Pain Scores 
 Pain sensation associated with plasters was determined on a 
VAS. The pain intensity rating (i.e., VAS) was measured imme-
diately after plaster application and immediately upon removal. 
The VAS was determined by asking the volunteers to mark on 
a 10 cm line, anchored by word descriptors at each end (“No 
Pain  = 0 cm” and the other end the “Worst Pain Imaginable  = 
10 cm). The volunteers mark on the line the point that he or she 
feels represents their perception of their current state. The VAS 
score is determined by measuring in centimeters from the left 
hand end of the line to the point that the volunteer marks. [ 33 ] 
 2.11. Transepidermal Water Loss 
 TEWL was measured to determine the level of disruption to 
skin barrier function following application of the plasters. 
The Vapometer was used to measure TEWL at a control site 
(previously marked with squares of  ≈ 1.5 cm 2 areas) pre- and 
post-application of plasters. TEWL measurements have been 
established as a routine method for evaluating the integrity of 
skin, which has been subjected to either physical or chemical 
treatment. [ 34 , 35 ] TEWL measurements were taken by carefully 
resting the TEWL probe horizontally on the application site, 
with the probe head vertical and perpendicular to the skin. 
L-glutamine, 10% foetal calf serum, 1.0 IU ml  − 1 penicillin and 
1.0  μ g ml  − 1 streptomycin. After 24 h of application, the DMEM 
solution was collected and sterile fi ltered. The medium (100%, 
50% and 10% diluted in fresh DMEM) was exposed to cell 
monolayers of Balb3T3 and NRERT-1 keratinocytes at 1  × 10 4 
cells ml  − 1 in the 96-well culture plate for 24 hrs. Following 24 h 
incubation at 37  ° C, the test extracts were assessed for cell 
viability by means of the quantitative MTT assay at 540 nm 
(Biotrak II Plate Reader, Amersham Biosciences, Cambridge, 
UK). A total of six replicates were studied for each extract, 
including control (sterile DMEM media) in the same plate. In 
3D keratinocyte organotypic raft type culture studies, the 3D 
keratinocyte tissues were pre-incubated (at 37  ° C and 5% CO 2 ) 
for 1.0 h in assay medium before starting the experiment. Prior 
to dosing with MN extract the assay medium was renewed. An 
aliquot (50  μ L) MN extract (undiluted) was applied atop the tis-
sues in triplicate and incubated for 24.0 h. At the end of the 
exposure period, the tissue cultures were gently rinsed with 
PBS, incubated in fresh medium for a further 24.0 h and fi nally 
placed into plates containing 0.5 mg ml  − 1 of MTT solution at 
1.0 ml cm  − 2 cultured tissue (4.0 ml). Following 3.0 h incuba-
tion and a rinse with PBS, the reduced MTT was extracted by 
submerging the tissues in 2.0 ml of isopropanol and shaking 
for 2.0 h. The absorbance of the extraction solutions was again 
measured at 540 nm. The mean absorbance was calculated for 
each tested sample (undiluted MN extract). The mean result of 
the negative control (H 2 O) tissues was set to represent 100% 
viability. 
 2.8. In Vitro 3D Skin Irritancy Test 
 In vitro skin irritancy tests were performed by using a 3D 
reconstructed human skin model (EpiSkin, Skin Ethic Labo-
ratories, Lyon, France). The assay endpoint for irritancy meas-
urements was IL-1 α (Interleukin-1 alpha). An aliquot (10  μ l) of 
sterile-fi ltered hydrogel extract, obtained as described above, 
was exposed to the reconstructed epidermis of the EpiSkin skin 
model. A negative (PBS) and positive (5% w/v sodium dodecyl 
sulphate, SDS) control were also included in the protocol. In 
each case, the epidermis of EpiSkin skin model was exposed 
at room temperature, according to the manufacturer’s recom-
mendations. Following exposure for 24 h, EpiSkin™ constructs 
were washed with PBS, and transferred to wells that contained 
fresh maintenance medium, and allowed to recover for 42 h at 
37  ° C, 5% CO 2 . The IL-1 α content of the recovery medium was 
assessed using a human IL-1 α specifi c ELISA (Thermo Scien-
tifi c/Pierce, IL, USA). 
 2.9. Human Volunteer Studies 
 In this study, gamma-sterilised hydrogel-forming MN were 
applied to the ventral forearm skin of six healthy human volun-
teers (3 men and 3 women, aged between 23 and 31 years), with 
no pre-existing skin conditions. They were asked not to wash or 
apply any cosmetic formulations on the ventral forearm during 
the study period. The School of Pharmacy’s Ethical Committee, 
Queen’s University Belfast, approved this study. 
Adv. Funct. Mater. 2012, 22, 4879–4890
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TEWL measurements recorded for a period up to 4 hours fol-
lowing patch removal 
 2.12. Clinical Scoring 
 Clinical scoring was used to determine irritation threshold in all 
study volunteers. Clinical scores were based on visual inspec-
tion following guidelines of the International Contact Derma-
titis (ICD) Research Group and the North American Contact 
Dermatitis Group. Clinical photographs of the skin before and 
after plaster application were captured using a Nikon D40X 
digital camera equipped with a Nikon AF-S VR Micro-Nikkor 
105 mm f/2.8G IF-ED lens and a Nikon Close-up Speedlight 
Commander Kit R1C1 with two wireless remote Speedlight 
SB-R200 fl ash units (Nikon UK Ltd, Kingston, UK) mounted 
on a ring on either side of the lens and using aperture priority. 
The camera was fi xed on a tripod and was adjusted to know 
height so that the distance between the ventral forearm and the 
camera lens were consistent throughout the study. Images were 
then printed on high quality photographic paper and were eval-
uated and scored blindly by two-experienced dermatologists. 
A clinical score for each test site was assigned, using the ICD 
scores. ICD scores were rated as 0, 0.5, 1, 2 or 3, which repre-
sent either: a negative, a barely perceptible macular erythema, 
a mild erythema, a moderate-intense uniform erythema or an 
intense erythema, vesiculation or erosion, respectively. [ 36 , 37 ] 
Optical coherence tomographic (OCT) studies, which allowed 
measurement of depth of MN insertion and permitted study of 
in-skin swelling, were conducted as described previously. [ 16 ] 
 2.13. Statistical Analysis 
 Physical characterisation data and in vitro drug permea-
tion experiments were analysed using a One-Way Analysis of 
Variance (ANOVA), with Tukey’s HSD post-hoc test. Compar-
isons for animal studies, cell culture work and human volun-
teer investigations were made using the Kruskal-Wallis tests 
and the Mann-Whitney U-test. In all cases  p  < 0.05 denoted 
signifi cance. 
 3. Results and Discussion 
 3.1. Mechanical Characterisation 
 We studied the mechanical properties of MN prepared from a 
hydrogel-forming formulation selected as a result of our pre-
vious work with such materials. [ 11–13 ] Here we report on fi ve 
mechanical tests; axial and transverse deformation, skin pene-
tration, MN base plate deformation and break. Increase in axial 
forces caused a progressive reduction in MN height, shown 
in Figure  2 b. The mean percentage reduction in MN height 
was 12.12, 18.18, 25.21, 50.21 and 58.65%, at applied forces 
of 0.05, 0.18, 0.36, 0.71 and 1.42 N per needle, respectively. 
Figure  2 c–e indicate that, even at the highest axial force, com-
plete MN failure was not observed, indicating residual viscoe-
lasticity, despite the relatively high glass-transition temperature 
(T g ) of this material (55.82  ± 0.97  ° C). Application of forces at 
right angles to the axes of the MN caused progressive reduc-
tions in MN height by bending. For example, at forces of  ≈ 0.06 
and 0.51 N per needle, the percentage reductions in MN height 
were  ≈ 24 and 57%, respectively. Figure  2 f,g shows representa-
tive digital images of MN after transverse force application. It 
was observed that insertion forces as low as 0.03 N per needle 
resulted in 100% of our MN penetrating the  stratum corneum of 
neonatal porcine skin (thickness 400  μ m) in vitro, as evidenced 
by methylene blue staining in Figure  2 i. In contrast, Figure  2 j 
shows the force required to break the hydrogel MN base-plates 
was approximately 23.55 N. At break point, the MN baseplate 
had bent to an angel of approximately 79.28º. This refl ects not 
only the considerable strength of the material, but also its con-
formability, important since, on a micron-scale, the skin is not 
perfectly fl at. Hence, MN arrays must ideally have a degree of 
fl exibility in their baseplate to ensure all MN penetrate the skin 
when applied. While this is true for the system described here, 
the same cannot be said for silicon, where we have seen that 
hard brittle baseplates can fracture upon application. 
 3.2. In Vitro Release Studies 
 For successful passive transdermal transport, molecules should 
ideally have intermediate Log P (1–3) values and molecular 
weights less than 500 Daltons. [ 1 , 14 ] A wide range of techniques 
aimed at bypassing the  stratum corneum barrier have success-
fully overcome these limitations. However, tape-stripping, 
sonophoresis, electroporation and heat/laser ablation are all 
much less practical than MN technology, which has been 
widely acclaimed for its potential to realise considerable patient 
benefi t in the near future. Recently, we have demonstrated a 
signifi cant enhancement in transdermal insulin transport in 
vitro using our dissolving poly(methylvinylether-co-maleic 
acid) (PMVE/MA) MN. [ 10 ] While percutaneous administration 
of these insulin-loaded MN arrays to diabetic rats resulted in 
a dose-dependent hypoglycaemic effect, sustained administra-
tion was limited by the fact that only the insulin contained in 
the needles themselves was released. This is an acknowledged 
problem for macromolecule-loaded dissolving polymeric MN. 
Since this is the type of MN system that currently shows the 
most promise and due to the ever-increasing number of macro-
molecular drugs with delivery problems, solutions are urgently 
required. In the present study, we have for the fi rst time, dem-
onstrated MN-mediated sustained percutaneous delivery of 
both low and high molecular weight compounds. 
 When drug-loaded patches were attached to drug-free 
hydrogel-forming MN and the integrated devices applied to der-
matomed neonatal porcine skin in vitro, controlled drug admin-
istration was achieved, with rates and extents of permeation 
independent of molecular weight and Log P values ( Figure  3 ). 
The demonstrated ability to deliver relatively small water sol-
uble molecules in milligram per square centimeter amounts 
in a sustained fashion is likely to be of great value to industry 
and, ultimately, patients. Most conventional drugs are small 
water soluble molecules and many treatment regimes would 
benefi t from the enhanced bioavailability and reduced dosing 
frequency that transdermal delivery offers. The biotechnology 
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using MN coupled with iontophoresis (ITP) may allow rapid 
delivery of vaccines or hormones (e.g., insulin), as well as ena-
bling delivery of conventional drug substances to be precisely 
controlled. [ 17 , 18 ] Ultimately, this may enable bolus, pulsatile or 
responsive drug administration. Combination of MN and ITP 
has shown to lead to a synergistic enhancement in transdermal 
delivery of a range of molecules. [ 17–21 ] However, the necessity for 
a two-stage application process (MN applied and removed, then 
ITP applied) when using this approach may be cumbersome 
for clinicians and patients, particularly given the importance of 
ensuring that the drug-loaded formulation is placed correctly 
over the microporated skin area. Secondly, it is known that the 
process of skin closure begins almost immediately upon MN 
removal, unless the skin area is kept under heavy occlusion. [ 7 ] 
This effectively limits the time available for enhanced drug 
delivery. Such problems may be overcome by the amalgamation 
of ITP with in situ polymeric MN delivery systems. As such, 
the present study evaluated the potential for the combination of 
our novel hydrogel MN devices and ITP. 
 Figure 4 a–e illustrates the combined effect of ITP and inte-
grated hydrogel MN on permeation of fi ve different solutes 
across dermatomed neonatal porcine skin. In general, the 
combination of ITP with the novel hydrogel MN array led to a 
boom continues to produce peptide and protein drugs with great 
potential. However, most of these exciting new drugs must be 
dosed parenterally, due to their high molecular weights, extreme 
hydrophilicities and propensity for gastrointestinal destruction. 
Here we have shown sustained transdermal transport of a pep-
tide and protein in milligram per square centimeter amounts 
over a 24 hour period. Importantly, we have previously demon-
strated that the nature of this hydrogel formulation can easily 
be altered on a case-by-case basis to improve delivery, [ 11–13 ] sug-
gesting utility in delivery of a range of macromolecules. 
 3.3. Combined Effect of ITP and Integrated MN 
 MN have been widely hailed as exciting alternatives to 
parenteral injection, complete with enhanced ease of use and 
reduced potential for transmission of infection. However, MN-
based delivery typically relies on relatively slow drug diffusion 
through MN-induced holes in the  stratum corneum or dissolu-
tion of drug-loaded polymeric MN or drug coatings on silicon 
or metal MN. This is in stark contrast to the rapid delivery pos-
sible using conventional needles and syringes. It has recently 
been proposed that the combination of skin barrier impairment 
 Figure  3 .  In vitro cumulative permeation results of different drug molecules delivered from integrated hydrogel-forming MN across dermatomed 
neonatal porcine skin of 300  ± 50  μ m thickness. a) In vitro permeation of FITC-BSA at a loading of 5 mg cm  − 2 from adhesive patches, integrated MN 
and integrated MN prepared from aqueous blends containing 3% w/w of NaHCO 3 . b) In vitro permeation of insulin from adhesive patches alone (at 
a loading of 5 mg cm  − 2 ), from integrated MN (at a loading of 2.5 mg cm  − 2 ), from integrated MN (at a loading of 5 mg cm  − 2 ) and from integrated MN 
prepared from aqueous blends containing 5% w/w of NaHCO 3 (at a loading of 5 mg cm  − 2 ). c) In vitro permeation of TP at a loading of 2.45 mg cm  − 2 
from adhesive patches and integrated MN. d) In vitro permeation of MZT at a loading of 4.20 mg cm  − 2 from adhesive patches and integrated MNs. 
e) In vitro permeation of CAF at a loading of 9 mg cm  − 2 from adhesive patches and integrated MN. f) In vitro permeation of MB at a loading of 3 mg 
cm  − 2 from adhesive patches and integrated MN. g) Table indicating the amount of each solute molecule released, in both  μ g and percentages, at the 
end of 24 h study period. Means  ± SD, n  = 4,  ∗ indicates permeation observed after 48 h. ND in (g) indicates not determined. 
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 3.4. In Vivo Studies 
 In order to demonstrate the utility and advantages of our novel 
hydrogel MN technology, we carried out a range of in vivo rat 
experiments ( Figure  5 a–f). Application of integrated hydrogel 
MN arrays resulted in a controlled reduction in blood glu-
cose levels (BGL) in diabetic rats. BGL dropped to  ≈ 90% of its 
original level within 2 h and fell further to  ≈ 37% by the end 
of the 12 h experimental period. Anodal ITP alone (applied 
for a 2 h period, after which the electrodes and insulin-loaded 
adhesive patch were removed) resulted in a maximal drop in 
BGL to  ≈ 61% of its original BGL value within 6 h, with BGL 
returning to normal by 12 h. The combination of integrated 
hydrogel MN and anodal ITP (applied for a 2 h period, after 
which the electrodes and MN/insulin patch were removed) led 
to a rapid reduction in BGL, dropping to  ≈ 47% within 2 h and 
 ≈ 32% within 6 h, before returning to normal values by 12 h. It 
was observed that the combined effect of integrated hydrogel 
MNs and ITP showed a signifi cantly greater C max (maximum% 
decrease in BGL value) (70.42  ± 1.86%) than ITP alone 
(39.06  ± 2.10%) ( p  < 0.001) or MN alone (63.16  ± 2.82%) 
( p  < 0.001). Furthermore, the time taken to reach this value was 
signifi cantly reduced through the combination of integrated 
MN and ITP (4 h), in comparison to ITP (6 h) ( p  < 0.001) or 
MN alone (12 h) ( p  < 0.001). 
 Sustained transdermal delivery of the high-molecular weight 
protein FTIC-BSA was clearly observed following application of 
greater rate and overall extent of transdermal delivery, in com-
parison to integrated MN alone. However, signifi cant enhance-
ments were only observed for the biomolecules insulin and 
FITC-BSA. This was particularly notable for FITC-BSA and is 
understandable, given the approximate 12,000 Dalton cut-off 
associated with conventional ITP. [ 1 , 19 ] 
 In an additional ex vivo experiment, optical coherence tom-
ographic (OCT) analysis revealed that application of an elec-
trical current leads to a dramatic increase in the swelling of 
the hydrogel-forming MN. It can be seen in Figure  4 f–i that, 
1 h after MN insertion into rat skin, MN height increased from 
 ≈ 610 to 650  μ m, whilst the MN base width increased from 
 ≈ 307  μ m to 360  μ m. However, following application of an 
electrical current for 1 h, MN height increased to  ≈ 1076  μ m 
(p  < 0.001), and the MN base width to approximately 802  μ m 
(p  < 0.001). This equates to an approximate 5.75-fold increase 
in MN surface area, in comparison to integrated hydrogel MN 
swelling under passive conditions. Such pronounced dimen-
sional changes, most likely due to enhanced water uptake by 
electoosmosis as we have previously postulated for the PEG-
crosslinked PMVE/MA system, [ 13 ] may partially explain the 
enhancements in delivery observed. The ability of these MN to 
imbibe skin interstitial fl uid is likely to fi nd use in minimally-
invasive patient monitoring, since drug concentrations in skin 
interstitial fl uid frequently refl ect those in plasma. [ 22 ] This 
would overcome many of the problems associated with direct 
blood sampling. 
 Figure  4 .  Combined effect of ITP and integrated hydrogel-forming MN on in vitro permeation of different drug molecules across dermatomed neonatal 
porcine skin of 300  ± 50  μ m thickness and the effect of ITP on in-skin MN swelling. a–e) Cumulative permeation of TP, MB, FS, insulin and FITC-BSA, 
respectively. f) OCT assessment of changes in MN dimensions following insertion into rat skin for a period of 1 h ex vivo. g–i) Representative light 
microscopy images of hydrogel-forming MN; g before skin insertion, h) 1 h after insertion into skin and i) 1 h after insertion into skin and application of 
a continuous electric current of 0.5mA. j) A representative OCT image of a hydrogel-forming MN array following insertion into rat skin ex vivo and appli-
cation of an electric current of 0.5 mA for a period of 1 h. Scale bars represent a length of 300  μ m. Error bars in (a–f,h) indicate standard deviations. 
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literature, the minimum effective concentration for MZT is 
6  μ g ml  − 1 . [ 23 ] If MZT loading in the integrated MN was to be 
increased, the minimum effective concentration could easily 
be achieved over a prolonged period of time, negating the need 
for invasive intravenous infusion. One of the major advantages 
of the current hydrogel-based MN delivery system could be 
negating the need for hospitalisation, as required in infusion 
dosing. In the present study, MZT was used as a model drug. 
However, considering the potential of this new delivery system, 
drugs with narrow therapeutic indices, having a range of physi-
cochemical properties (log P/log D) and/or exhibiting stability 
problems in infusion media could be effi ciently delivered with 
this approach. 
 It was again observed that application of an electrical cur-
rent led to a marked increase in the rate and extent of in-skin 
swelling of the hydrogel-forming MN arrays. Importantly, as 
with in vitro studies, the integrated hydrogel MN arrays were 
removed fully intact following the complete period of applica-
tion in all animals, regardless of whether ITP was employed or 
not (Figure  5 h,i). This refl ects the retention of good mechanical 
strength by the swollen hydrogel and is likely to be of great 
importance as MN technology moves forwards towards com-
mercialization, given that regulatory authorities, healthcare 
professionals and ultimately patients may have concerns about 
integrated MN, with peak plasma concentrations reaching 
8.86  ± 1.49  μ g ml  − 1 at 24 h. The combination of integrated 
hydrogel MN and ITP led to a signifi cantly accelerated FTIC-
BSA permeation, with detectable FTIC-BSA levels found in 
plasma after only 30 min. Following termination of the elec-
tric current and complete removal of the MN device after 2 h 
of application, FTIC-BSA plasma levels were found to be 
3.89  ± 0.96  μ g ml  − 1 . This is  ≈ 4.8 fold greater than the 
0.81  ± 0.32  μ g ml  − 1 detected at the same period through the use 
of integrated hydrogel MN alone ( p  < 0.001). It was found that 
the FTIC-BSA plasma levels continued to rise to peak levels of 
4.92  ± 1.15  μ g ml  − 1 at 4 h. In contrast, application of an adhe-
sive FTIC-BSA-loaded patch, or the use of ITP alone, did not 
result detection of FTIC-BSA in plasma. 
 The low molecular weight hydrophilic drug metronidazole 
(MZT) was found to rapidly appear in plasma and maintained 
quite constant levels over the 48 h study period. The mean 
pharmacokinetic parameters of MZT, administered through the 
integrated MN, was determined by a non-compartmental anal-
ysis of the whole blood, where the C max was 4.64  ± 1.05  μ g ml  − 1 
at a T max of 4.67  ± 1.15 h (Figure  5 g). The mean area under 
the curve (AUC 0–48 h ) was found to be 172.24  ± 24  μ g h ml  − 1 . 
The C ss was calculated by dividing AUC 0–48 h with total study 
time (48 h) was found to be 3.59  ± 0.73  μ g ml  − 1 . Based on the 
 Figure  5 .  In vivo permeation studies in a rat model. a)% drop in blood glucose levels following delivery of insulin from patches alone and from inte-
grated hydrogel-forming MN. b) The% drop in blood glucose levels following application of an electric current (0.5 mA for 2 h) with the insulin-loaded 
patch and in combination with integrated hydrogel-forming MN. c) C max and T max values of insulin for the different delivery strategies shown in (a,b) 
investigated within the diabetic rat model in vivo. d) Plasma concentration of FITC-BSA delivered from integrated MN patches - no detectable FITC-
BSA was delivered from the patches alone. e) Plasma concentration of FITC-BSA delivered from integrated MN patches combined with ITP. f) The in 
vivo pharmacokinetic profi le of MTZ following delivery by integrated hydrogel-forming MN. g) The pharmacokinetic parameters (C max , T max and C ss ) 
of MZT in rats. h–i) Representative light microscopy images demonstrating that hydrogel-forming MN arrays remain intact; h) before insertion and i) 
after removal from a rat in an in vivo experiment after a 12 h application/insertion period. Scale bars represent a length of 300  μ m. Error bars in (a–f) 
indicate standard deviations. 
Adv. Funct. Mater. 2012, 22, 4879–4890
FU
LL
 P
A
P
ER
4888
www.afm-journal.de
www.MaterialsViews.com
wileyonlinelibrary.com © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
capable of being produced in a range of sizes to suit required 
drug doses. 
 3.6. Biocompatability 
 Biocompatibility of a given material can be tested by ISO and 
USP standards, [ 24 , 25 ] which principally depend upon expo-
sure of material to specifi c cells in vitro, using both direct 
and indirect contact approaches. Alternatively, 3D human 
cells cultures can also be used. [ 26 ] In these methods, leach-
able products from the material will, if toxic, induce mem-
brane damage and impairment of metabolic processes. The 
biocompatibility of our MN materials was evaluated in vitro 
using cell monolayers (Balb/3T3 and NRERT-1 keratinocytes) 
and a 3D skin model.  Figure  6 a,b shows no signifi cant reduc-
tion in cell viability in all three tests. Skin irritancy studies 
(Figure  6 c), showed that exposure to SDS elicited a signifi cant 
increase in production of the irritancy biomarker cytokine 
interleukin-1 α (IL-1 α ) in a 3D skin model when compared 
local or systemic reactions that may occur if portions of the 
needle were to break within the skin. It is our assertion that 
these integrated hydrogel MN are well-suited for sustained 
delivery of both small water soluble drugs and also higher 
molecular weight peptide and protein molecules. Pulsatile 
delivery can be achieved through application of ITP to meet on-
demand requirements (e.g., delivery of insulin after a meal) or 
for rapid vaccine delivery. 
 3.5. Safety and Scalable Production 
 All drug delivery systems must not only be effective, they 
must also be completely safe for patient use. Accordingly, 
much current effort is focussed on MN prepared from FDA-
approved polymeric materials, rather than silicon or metal. 
Such systems will also need to be shown to be safe, since 
administration of these polymers by the intradermal route is 
completely new. Sterility, or low bioburden, is likely to be a 
prerequisite for regulatory approval, while MN arrays must be 
 Figure  6 .  In vitro and in vivo safety studies for hydrogel-forming MN. a–c) Results of cytotoxicity studies in cell lines; a) in Balb/NRERT-1 keratinocyte 
cell lines; b) in 3D-keratinocyte cells lines; c) IL-1 α expression by EpiSkin constructs in control conditions and on exposure to a 24 h aqueous extract 
of hydrogel microneedles. d) A representative pattern of application of four different plasters on the ventral forearms of human volunteers. e–i) Repre-
sentative samples of clinical photographs taken to measure the ICD scores in human volunteers in a 24 h treatment group by expert dermatologists; 
e) before application of MN (ICD  = 0); f) after removal of plaster only (ICD  = 0); g) after removal of plasters containing MN baseplates only (ICD  = 
0); h) after removal of plasters containing 11  × 11 hydrogel-forming MN array (ICD  = 0.5); i) after removal of plasters containing 19  × 19 hydrogel-
forming MN array (ICD  = 1). j) The mean ICD scores in human volunteers following removal of the two different densities of hydrogel-forming MN 
array in the 24 h treatment group. k) Mean TEWL values following removal of hydrogel-forming MN array in the 24 h treatment group. l) An OCT 
image 2 h following insertion of hydrogel-forming MN array (height 600  μ m, width at base 300  μ m, spacing 300  μ m, 11  × 11 array) into human skin 
in vivo. m shows a digital image of hydrogel-forming MN array containing approximately 18 000 MN needles in a 25 cm 2 area, the hydrogel needles 
can been seen in the inset. Error bars in (a–c,j,k) indicate standard deviations. The scale bar in (l) represents a length of 300  μ m, while the scale bar 
in m represents a length of 5 mm. 
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of the skin site were MN arrays had been applied returned to 
normal (i.e., 0) within 1 h of MN removal. Furthermore, MN 
arrays remained intact and no damage to the MN was noted 
during application, wear (as evidenced by OCT, Figure  6 l), or 
removal of MN-containing plasters. 
 Following removal of MN-containing plasters from the vol-
unteers, MN dimensional changes were measured. A greater 
increase in MN dimensions was noted for the higher density 
361 MN array in comparison to the 121 MN array ( p  < 0.001). 
MN height increased from 597.2  ± 7.4 to 731.2  ± 6.8  μ m and 
MN width at base from 306.9  ± 4.5 to 379.3  ± 5.2  μ m after 
24 h wear for the 361 MN array. In comparison, the MN height 
of the 121 array increased from 599.6  ± 6.9 to 686.8  ± 7.8  μ m, 
whilst the MN width at base increased from 305.8  ± 4.6 to 
359.4  ± 5.6  μ m, after residing in the skin of a human volunteer 
for a 24 h period. Overall, these values equate to an increase in 
MN surface area of 35.0%, and 51.5% for the 121 and 361 MN 
array designs, respectively. 
 Transepidermal water loss (TEWL) measurements, used 
worldwide to assess skin barrier function showed that the skin 
barrier returned to normal within 30 minutes of MN removal, 
regardless of the treatment protocol. Figure  6 k show the results 
of TEWL values for the 24 h treatment group. Similar trends 
in TEWL values were observed in the 0 h and 2 h treatment 
groups. 
 Interestingly, we found that MN removed from skin, even 
after 1 min insertion, were incapable of re-insertion, due to sof-
tening by rapid imbibing of skin interstitial fl uid. This is a fur-
ther important safety advantage over conventional MN designs. 
 3.8. Production 
 In order to be commercially viable, polymeric MN must be 
capable of large scale production. Manufacture of arrays with 
areas greater than 0.5–1 cm 2 will also be required in order to 
provide fl exibility of dosing for drugs with different therapeutic 
windows. Clearly, centrifuge-based mould fi lling is unsuitable 
for production of multiple arrays or arrays with large surface 
areas. In addition, there are no similar dosage forms currently 
produced by the pharmaceutical or medical devices industries. 
It is our assertion that MN manufacture should resemble pro-
duction of conventional transdermal patches as closely as pos-
sible. Accordingly, we used knife casting to spread aqueous 
PEG-containing PMVE/MA gels on laser engineered silicone 
moulds without sidewalls. The moulds were then placed in 
a vacuum chamber. This resulted in fully-formed MN arrays. 
The maximum patch size produced by us to date is 25 cm 2 , 
containing approximately 18,000 individual MN (Figure  6 m). 
 4. Conclusion 
 We have shown for the fi rst time that MN can be successfully 
prepared from hydrogel-forming materials. Such MN swell 
in skin to produce continuous, unblockable conduits from 
patch-type drug reservoirs to the dermal microcirculation, thus 
allowing prolonged transdermal drug administration. Pulsatile 
or bolus delivery can be achieved under electrical control, while 
to both control and hydrogel MN extract. These results sug-
gest that the hydrogel-based MN material is likely to be both 
biocompatible and non-irritant. 
 3.7. Sterilization and Human Volunteer Studies 
 Both aseptic manufacture and post-manufacture gamma steri-
lization rendered MN sterile, as evidenced by the BP Sterility 
Test. [ 27 ] Gamma-sterilised ( 60 Co, 10 kGy) MN were applied to 
the ventral forearm skin of six healthy human volunteers. 
Application of a conventional sticking plaster only and the 
plaster containing the MN baseplate received a VAS score of 
0 cm (i.e., no pain was felt at all) in all volunteers. However, 
application of plasters containing MN arrays elicited higher 
VAS scores, which were dependent upon the density of the MN 
array applied. For example, the mean VAS score associated with 
application of the hydrogel MN of density 361 MN per 0.5 cm 2 
(0.33  ± 0.10 cm) was greater than that for a hydrogel MN of 
density 121 MN per 0.5 cm 2 (0.14  ± 0.08) ( p  < 0.001). Similarly, 
both hydrogel MN systems had greater recorded VAS score 
during wear for both the 2 h and the 24 h application groups. 
VAS scores were increased for both MN array designs during 
the 24 h treatment protocol, in comparison to the 2 h treatment 
protocol. Comments from volunteers regarding sensations 
included: “A prickly feeling noticed at times during the pres-
ence of 361 array”; “Slight pressure noticed for 361 array about 
10 h after application, but not classed as pain”; “Defi nitely feel 
a sensation during 361 array application, like a scratch”; “Could 
feel pressure during 361 array presence, slight itchy feeling” 
and “For 24 h period, slight itchy feeling at night for the 361 
array”. 
 Figure  6 l shows representative cross-sectional OCT images 
of 121 MN arrays inserted in human skin in vivo. The images 
confi rm that the MN punctured the  stratum corneum barrier 
and the MN extended  ≈ 460  μ m into the skin. The widths of 
the MN induced holes in the  stratum corneum were  ≈ 265  μ m 
in diameter. However, it is obvious that there was a clear space 
of  ≈ 136  μ m between the bottom of the MN baseplate and 
the upper surface of the  stratum corneum , indicating that the 
entirety of the MN lengths were not inserted into the skin. 
When the 361 MN array were inserted into the skin of human 
volunteers, it was found that the MN extended approximately 
440  μ m into the skin and that the holes in the  stratum corneum 
were  ≈ 258  μ m in diameter. Once again, a clear space of approx-
imately 156  μ m between the bottom of the MN baseplates and 
the upper surface of the  stratum corneum was observed. 
 Figure  6 d–i show sample clinical photographs for a 24 h 
treatment protocol. The irritant contact dermatitis (ICD) scores 
indicated no reaction with the plaster only treatment, whilst 
only one individual had a response graded as 0.5 for the plaster 
containing the MN baseplate only. The skin response following 
application of the MN-containing plasters was graded as only 
barely perceptible (0.5) or mild erythema (1), regardless of the 
length of time the MN array remained within the skin. Inter-
estingly, for the 0 h and 24 h treatment protocols, the grading 
of the skin response following removal of the patch containing 
a 361 MN array was lower than that for a patch containing a 
121 MN array, as shown in Figure  6 j. In all cases, ICD scores 
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MN are removed intact from skin. The ability of MN to imbibe 
skin interstitial fl uid may fi nd further use in minimally-invasive 
patient monitoring. MN materials were shown to be biocom-
patible and non-irritant in vitro and raised no safety concerns 
in human volunteers. This technology has the potential to over-
come the limitations of conventional MN designs and greatly 
increase the range of type of drug deliverable transdermally, 
with ensuing benefi ts for industry, healthcare providers and, 
ultimately, patients. We are actively pursuing commercialisa-
tion of the technology with two major companies. 
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